Table 3.
Vaccine effectiveness against AGE hospitalization during the post-vaccine period by age group
| Age Group | Direct VE, % (95% CI) |
Indirect VE, % (95% CI) |
Overall VE, % (95% CI) |
Total VE, % (95% CI) |
|---|---|---|---|---|
| < 1 | 59* (54, 64) | 25* (12, 36) | 49* (37, 58) | 69* (63, 74) |
| 1 | 63* (55, 69) | 38* (20, 52) | 59* (46, 68) | 77* (71, 81) |
| 2 | 57* (44, 66) | 28* (5, 46) | 49* (33, 62) | 69* (59, 76) |
| 3 | 60* (49, 68) | 16 (− 7, 34) | 42* (27, 55) | 67* (58, 74) |
| 4 | 54* (42, 64) | 11 (− 13, 29) | 33* (16, 46) | 60* (47, 70) |
| 0–4 | 56* (50, 61) | 27* (15, 38) | 48* (40, 55) | 68* (63, 72) |
| 5–9 | 33* (19, 45) | 16* (8, 24) | 20* (12, 27) | 44* (31, 55) |
*Represents significance at the alpha = 0.05 level